Second, studies should focus on highly metabolically active tumor groups that are also at lower malnutrition risk, for safety reasons, such as triple-negative (ER/PR/HER2-negative) breast cancers, melanoma, and high-grade lymphomas. This evidence concerns the gene ERBB2 and neoplasm.